Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine

Z Odabasi, A Karaalp, H Cermik, J Mohr, E T Tigen, M Koc, V Korten, Z Odabasi, A Karaalp, H Cermik, J Mohr, E T Tigen, M Koc, V Korten

Abstract

The reduction of amphotericin B (AmB)-induced renal tubular apoptosis and nephrotoxicity by N-acetylcysteine (NAC) in a murine model was evaluated. Four groups of rats were treated with AmB for 5 days, and each group concomitantly received two doses of 30, 60, or 120 mg of NAC/kg of body weight/day or sterile water for 5 days. Groups that received concomitant NAC at any dose had significantly decreased levels of apoptosis compared to that in animals receiving AmB only (48.8% versus 27.4, 23.6, or 23.5%, respectively; P < 0.001).

Figures

FIG. 1.
FIG. 1.
Photomicrographs of renal tubular cells (at a magnification of ×400). Apoptotic cells were detected immunohistochemically by in situ end labeling of DNA strand breaks (TUNEL assay). All dark-stained cells (white arrows) are apoptotic. (Left) Tubular epithelial cells from rats treated with 10 mg/kg AmB; (right) cells from rats treated concomitantly with AmB and 60 mg/kg/12 h of NAC for 5 days, showing a significant decrease in apoptosis.

References

    1. Appenroth, D., K. Winnefeld, H. Schroter, and M. Rost. 1993. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J. Appl. Toxicol. 13:189-192.
    1. Bakris, G. L., N. Lass, A. O. Gaber, J. D. Jones, and J. C. Burnett, Jr. 1990. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am. J. Physiol. 258:F115-F120.
    1. Bates, D. W., L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. Gomes, E. J. Dasbach, and R. Platt. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
    1. Briguori, C., A. Colombo, A. Violante, P. Balestrieri, F. Manganelli, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, P. Scarpato, A. Focaccio, M. Librera, E. Bonizzoni, and B. Ricciardelli. 2004. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur. Heart J. 25:206-211.
    1. Briguori, C., F. Manganelli, P. Scarpato, P. P. Elia, B. Golia, G. Riviezzo, S. Lepore, M. Librera, B. Villari, A. Colombo, and B. Ricciardelli. 2002. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 40:298-303.
    1. Bullock, W. E., R. G. Luke, C. E. Nuttall, and D. Bhathena. 1976. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob. Agents Chemother. 10:555-563.
    1. Caillot, D., G. Reny, E. Solary, O. Casasnovas, P. Chavanet, B. Bonnotte, L. Perello, M. Dumas, F. Entezam, and H. Guy. 1994. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J. Antimicrob. Chemother. 33:603-613.
    1. Caldicott, W. J., N. K. Hollenberg, and H. L. Abrams. 1970. Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Investig. Radiol. 5:539-547.
    1. Carrigan Harrell, C., and L. Hanf-Kristufek. 2001. Comparison of nephrotoxicity of amphotericin B products. Clin. Infect. Dis. 32:990-991.
    1. Eriksson, U., B. Seifert, and A. Schaffner. 2001. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322:579-582.
    1. Fanos, V., and L. Cataldi. 2000. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12:463-470.
    1. Feldman, L., S. Efrati, V. Dishy, L. Katchko, S. Berman, M. Averbukh, M. Aladjem, Z. Averbukh, and J. Weissgarten. 2005. N-Acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol. 99:p23-p27.
    1. Fishbane, S. 2008. N-Acetylcysteine in the prevention of contrast-induced nephropathy. Clin. J. Am. Soc. Nephrol. 3:281-287.
    1. Girmenia, C., G. Gentile, A. Micozzi, and P. Martino. 2001. Nephrotoxicity of amphotericin B desoxycholate. Clin. Infect. Dis. 33:915-916.
    1. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, R. M. Alfaro, C. King, S. C. Piscitelli, and T. J. Walsh. 2003. Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob. Agents Chemother. 47:3917-3925.
    1. Harbarth, S., S. L. Pestotnik, J. F. Lloyd, J. P. Burke, and M. H. Samore. 2001. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. 111:528-534.
    1. Herbrecht, R., S. Natarajan-Ame, Y. Nivoix, and V. Letscher-Bru. 2003. The lipid formulations of amphotericin B. Expert Opin. Pharmacother. 4:1277-1287.
    1. Imhof, A., R. B. Walter, and A. Schaffner. 2003. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36:943-951.
    1. Moreau, P., N. Milpied, N. Fayette, J. F. Ramee, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:535-541.
    1. Nitescu, N., S. E. Ricksten, N. Marcussen, B. Haraldsson, U. Nilsson, S. Basu, and G. Guron. 2006. N-Acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol. Dial. Transplant. 21:1240-1247.
    1. Nucci, M., M. Loureiro, F. Silveira, A. R. Casali, L. F. Bouzas, E. Velasco, N. Spector, and W. Pulcheri. 1999. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. 43:1445-1448.
    1. Odabasi, Z., A. Karaalp, H. Cermik, J. Mohr, O. Ergonul, Z. Agalar, B. Sumer, L. Mulazimoglu, and V. Korten. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1100, p. 22. American Society for Microbiology, Washington, DC.
    1. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
    1. Persson, P. B., and M. Tepel. 2006. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int. Suppl. 2006:S8-S10.
    1. Schoffski, P., M. Freund, R. Wunder, D. Petersen, C. H. Kohne, H. Hecker, U. Schubert, and A. Ganser. 1998. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 317:379-384.
    1. Solomon, R. 1998. Contrast-medium-induced acute renal failure. Kidney Int. 53:230-242.
    1. Sorkine, P., H. Nagar, A. Weinbroum, A. Setton, E. Israitel, A. Scarlatt, A. Silbiger, V. Rudick, Y. Kluger, and P. Halpern. 1996. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. 24:1311-1315.
    1. Tepel, M. 2003. Acetylcysteine for the prevention of radiocontrast-induced nephropathy. Minerva Cardioangiol. 51:525-530.
    1. Tepel, M. 2006. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 354:1853-1855.
    1. Tepel, M., M. van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek. 2000. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343:180-184.
    1. van den Berk, G., S. Tonino, C. de Fijter, W. Smit, and M. J. Schultz. 2005. Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients. Crit. Care 9:361-370.
    1. Varlam, D. E., M. M. Siddiq, L. A. Parton, and H. Russmann. 2001. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob. Agents Chemother. 45:679-685.
    1. Weisberg, L. S., P. B. Kurnik, and B. R. Kurnik. 1994. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 45:259-265.
    1. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.
    1. Wong-Beringer, A., R. A. Jacobs, and B. J. Guglielmo. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:603-618.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi